A Nanodrug Coated with Membrane from Brain Microvascular Endothelial Cells Protects against Experimental Cerebral
Wei Wei1, Weijia Cheng2, Wenhao Dai1
1Beijing Key Laboratory for Bioengineering and Sensing Technology, School of Chemistry and Bioengineering, University of Science and Technology Beijing, Beijing 100083, China.
Abstract:
Human malaria is a global life-threatening infectious disease. Cerebral malaria (CM) induced by Plasmodium falciparum parasites accounts for 90% of malaria deaths. Treating CM is challenging due to inadequate treatment options and the development of drug resistance. We describe a nanoparticle formulation of the antimalarial drug dihydroartemisinin that is coated in a biomimetic membrane derived from brain microvascular endothelial cells (BMECs) and test its therapeutic efficacy in a mouse model of experimental cerebral malaria (ECM). The membrane-coated nanoparticle drug has a prolonged drug-release profile and enhanced dual targeting killing efficacy toward parasites residing in red blood cells (iRBCs) and iRBCs obstructed in the BMECs (for both rodent and human). In a mice ECM model, the nanodrug protects the brain, liver, and spleen from infection-induced damage and improves the survival rate of mice. This so-called nanodrug offers new insight into engineering nanoparticle-based therapeutics for malaria and other parasitic pathogen infections.
Insights
A new nanoparticle drug effectively treats cerebral malaria (CM) in mice. This biomimetic nanodrug targets malaria parasites in red blood cells and brain vessels, improving survival rates and reducing organ damage.
Area of Science:
- Biomedical Engineering
- Infectious Diseases
- Nanotechnology
Background:
- Human malaria, particularly cerebral malaria (CM), is a life-threatening disease with limited treatment options and increasing drug resistance.
- Plasmodium falciparum causes 90% of malaria deaths, with CM being the most severe form.
Purpose of the Study:
- To develop and evaluate a novel nanoparticle formulation of dihydroartemisinin for treating experimental cerebral malaria (ECM).
- To assess the therapeutic efficacy of a biomimetic membrane-coated nanoparticle drug in a mouse model of ECM.
Main Methods:
- A nanoparticle formulation of dihydroartemisinin was coated with a biomimetic membrane derived from brain microvascular endothelial cells (BMECs).
- The efficacy of the membrane-coated nanodrug was tested in a mouse model of experimental cerebral malaria (ECM).
- Drug release profile and targeting efficacy against infected red blood cells (iRBCs) and those obstructing BMECs were analyzed.
Main Results:
- The nanodrug exhibited a prolonged drug-release profile and enhanced dual targeting efficacy against parasites.
- Treatment with the nanodrug protected the brain, liver, and spleen from ECM-induced damage in mice.
- The nanodrug significantly improved the survival rate of mice in the ECM model.
Conclusions:
- Biomimetic membrane-coated nanoparticles represent a promising strategy for engineering advanced therapeutics against malaria.
- This nanodrug formulation offers new insights for developing treatments for malaria and other parasitic infections.
- The enhanced targeting and efficacy of the nanodrug suggest potential for improved clinical outcomes in cerebral malaria patients.
